Samsung Biologics announced a major expansion of its global footprint by agreeing to purchase a U.S. drug production facility from pharmaceutical giant GlaxoSmithKline. The deal marks the South Korean contract manufacturer’s first acquisition of a U.S. manufacturing site and represents a significant step in its long-term strategy to strengthen operations in a key market.
Under the terms of the agreement, Samsung Biologics America, the company’s U.S. subsidiary, will acquire 100% ownership of Human Genome Sciences Inc and its Rockville, Maryland plant for about $280 million. The transaction is expected to close by the end of the first quarter of 2026 after regulatory and customary approvals.
The Rockville facility holds two manufacturing plants that together offer a 60,000-liter drug substance capacity. This scale supports both clinical-stage and commercial production, enabling Samsung Biologics to serve a broad range of clients and therapeutic programs. The company has signaled plans to invest further in the site to expand capacity and modernize technology, enhancing resilience in the U.S. biopharma supply chain.
Retention of the existing workforce is part of the deal. More than 500 employees currently working at the facility will remain in place following the transition. Maintaining this experienced labor force aims to ensure continuity of operations and minimize disruption to ongoing manufacturing contracts and production schedules.
Industry analysts see the acquisition as a strategic response to broader trends in global pharmaceutical manufacturing. Companies around the world have been boosting U.S. presence to mitigate supply-chain risk and navigate shifting trade policies, including tariff pressures that could affect foreign drug imports. Establishing local production capabilities helps multi-national firms stay competitive and responsive to American demand for biologics and complex therapies.
For Samsung Biologics, this purchase complements its already large manufacturing footprint in South Korea, where it operates several high-capacity facilities. The company is known for contract development and manufacturing services (CDMO), providing end-to-end solutions for biologic treatments including monoclonal antibodies, antibody-drug conjugates, and other advanced modalities. The Maryland acquisition gives it a strategic base in one of the largest pharmaceutical markets in the world.
From GSK’s perspective, divesting the Rockville plant enables a sharper focus on other priorities such as research and development investment, pipeline innovation, and expansion of next-generation therapeutics. The company has also recently pledged multibillion-dollar investments in U.S. R&D and manufacturing infrastructure over the next several years, reflecting a dual approach of internal development and strategic partnerships.
The transaction positions Samsung Biologics to offer multi-site manufacturing flexibility to its global customers. Firms seeking reliable production options now have a combined network spanning the U.S. and South Korea, which could prove valuable for scaling programs across different regions while meeting regulatory and supply expectations.
Market reaction to the announcement was modest, with Samsung Biologics’ shares inching slightly lower on the day. The broader industry continues to watch how regulatory pressures, supply-chain considerations, and trade policies influence manufacturing decisions and cross-border investments in the pharmaceutical sector.
As the deal moves toward completion, Samsung Biologics’ acquisition of the Rockville facility stands out as a key development in the CDMO space. It reflects how companies are adapting production strategies to ensure resilience, proximity to large patient markets, and robust manufacturing capabilities for complex biologic medicines.
